Nightingale Health Signs $1M Alzheimer’s Research UK Proteomics Agreement
Nightingale Health will analyze 10,000 UK Biobank samples using Alamar’s NULISAseq Neuro 220 panel, with data delivered to UK Biobank for research use.
Related stories
DXN Posts Q1 FY27 Revenue of A$3.4 Million
DXN reported Q1 FY27 revenue of A$3.4 million.
M impact | EQUITY | Oct 30, 2026, 01:32 AM UTC
Shanghai Composite Falls Below 3,600 in Morning Trading
L impact | EQUITY | Oct 30, 2026, 01:31 AM UTC
Timberland Bancorp Q4 Earnings Snapshot
Timberland Bancorp reported net income for its fiscal fourth quarter.
M impact | EQUITY | Oct 30, 2026, 01:31 AM UTC
Asian session market picture: S&P 500 -0.99%, Nasdaq 100 -2.3%; USD/JPY -0.19%, WTI +0.77%, 1810 leads volume
Asian session market picture. US index futures: S and P futures is down 0.99 percent, Nasdaq futures is down 2.3 percent, Dow futures is down 0.14 percent and Russell futures is do
M impact | EQUITY | Oct 30, 2026, 01:30 AM UTC
Rent.com.au Reports Quarterly Group Revenue of A$1.53 Million
M impact | EQUITY | Oct 30, 2026, 01:29 AM UTC
HanmiGlobal Wins 59.5 Billion Won Order
M impact | EQUITY | Oct 30, 2026, 01:29 AM UTC